AVROBIO Inc (AVRO)

$ 8.6
-0.15 (-1.71%)
-
Symbol AVRO
Price $ 8.6
Beta 1.394
Volume Avg. 0.72M
Market Cap 0.36B
Shares () -
52 Week Range 8.05-23.5
1y Target Est -
DCF Unlevered -
DCF Levered -
ROE -49.96% Strong Sell
ROA -44.14% Strong Sell
Operating Margin -
Debt / Equity 6.64% Neutral
P/E -
P/B 1.23 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against AVROBIO, Inc. and Encourages Investors with Losses to Contact the Firm

ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against AVROBI...

LOS ANGELES, May 6, 2021 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of AVROBIO, Inc. ("AVROBIO" or "the Company") (NASDAQ: AVRO) for violations ... ...

PRNewsWire
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against AVROBIO, Inc. and Encourages Investors with Losses to Contact the Firm

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against AVROBIO, In...

LOS ANGELES--(BUSINESS WIRE)---- $AVRO #AVRO--INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against AVROBIO, Inc. ...

Business Wire
AVROBIO: Fabrazyme's Full Approval Changes Things

AVROBIO: Fabrazyme's Full Approval Changes Things

AVROBIO: Fabrazyme's Full Approval Changes Things ...

Seeking Alpha
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against AVROBIO, Inc. and Encourages Investors with Losses to Contact the Firm

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against AVROBIO, Inc. ...

LOS ANGELES--(BUSINESS WIRE)---- $AVRO #AVRO--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against AVROBIO, Inc. ...

Business Wire
BREAKING ALERT: Rosen Law Firm Encourages AVROBIO, Inc. Investors with Losses to Inquire About Class Action Investigation – AVRO

BREAKING ALERT: Rosen Law Firm Encourages AVROBIO, Inc. Investors with Losses to Inquire About Class...

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of AVROBIO, Inc. (NASDAQ: AVRO) resulting from allegations that AVROBIO may have is... ...

Business Wire
Avrobio Plans Registration Trial With Kidney Biopsy Endpoint To Support Potential Full Approval Of Fabry Disease Gene Therapy

Avrobio Plans Registration Trial With Kidney Biopsy Endpoint To Support Potential Full Approval Of F...

Avrobio Inc (NASDAQ: AVRO) has provided an update on its regulatory plans for AVR-RD-01, its lentiviral gene therapy for Fabry disease, currently in FAB-GT Phase 2 trial. In March, the FDA granted full approval to Sanofi's SA (NASDAQ: SNY) Fabrazyme ... ...

Benzinga
AVROBIO Provides Regulatory Update on Investigational AVR-RD-01 for Fabry Disease

AVROBIO Provides Regulatory Update on Investigational AVR-RD-01 for Fabry Disease

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today provided an update on its regulatory plans for AVR-RD-01,... ...

Business Wire
Rocket Pharmaceuticals Primed for Takeoff

Rocket Pharmaceuticals Primed for Takeoff

With all due respect to Elton John, the real Rocket Man is in Cranbury, New Jersey. ...

GuruFocus
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted non-statutory stoc... ...

Business Wire
Avrobio's Cystinosis Gene Therapy Gets Orphan Drug Status In Europe

Avrobio's Cystinosis Gene Therapy Gets Orphan Drug Status In Europe

The European Commission has designated Orphan Drug status to Avrobio Inc's (NASDAQ: AVRO) AVR-RD-04, its gene therapy to treat cystinosis. AVR-RD-04 consists of the patient's hematopoietic stem cells, genetically modified to express cystinosin, the p... ...

Benzinga

About


Mr. Geoff MacKay
Healthcare
Biotechnology
Nasdaq Global Select

AVROBIO, Inc., a clinical-stage gene therapy company, focuses on developing ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose in the United States. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene, which is defective in the target disease. The company's lead product candidate is AVR-RD-01, which is in ongoing Phase II clinical trial and investigator-sponsored Phase I clinical trial for the treatment of Fabry disease. It is also developing AVR-RD-02 that has completed pre-clinical trials for the treatment of type 1 Gaucher disease; AVR-RD-03, which is in preclinical development to treat Pompe disease; and AVR-RD-04 that has completed pre-clinical studies for treating cystinosis. The company has a research and clinical collaboration agreement with Magenta Therapeutics to evaluate targeted antibody-drug conjugate as a conditioning regimen for lentiviral gene therapies. AVROBIO, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.